Post List #1

2026

Role of supportive care in the future of cell therapies. Cell & Gene Therapy Insights 2026; 12(1), 81–86

Liam Tremble, Paula Maguire
Read more
2024

POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, PhD, MSc, BSc, Paula Maguire, PhD, Jiwon Yang, PhD, James G Keck, Laura Maher, MSc, Mark Graham, Martin F Kaiser, MD, FRCP, FRCPath, Emma Searle, MD, PhD and Mark Sumeray, MD
Read more
2023

POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

E. Searle, L.F. Tremble, R. Popat, D.T. de Bruin, M. Moerland, B. Buckley
Read more
2023

Inhibition of local and systemic inflammatory responses by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS administration in healthy volunteers

D.T. de Bruin, M.A.A. Jansen, J. Skillington, L. Tremble, S. Rajbally, N.B. Klarenbeek, M. Moerland
Read more
Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.